openPR Logo
Press release

Investigation announced for Investors in shares of IMARA Inc. (NASDAQ: IMRA)

03-24-2021 12:07 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in IMARA Inc. (NASDAQ: IMRA) shares over potential securities laws violations by IMARA Inc.

An investigation for investors in IMARA Inc. (NASDAQ: IMRA) shares over potential securities laws violations by IMARA Inc.

An investigation was announced concerning potential violations of securities laws by IMARA Inc. in connection with certain financial statements.

Investors who purchased shares of IMARA Inc. (NASDAQ: IMRA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by IMARA Inc. its business, its prospects and its operations were materially false and misleading at the time they were made.

Boston, MA based IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. On or around March 11, 2020, IMARA Inc. (NASDAQ: IMRA) conducted its initial public offering ("IPO"), selling 4,700,000 shares of common stock priced at $16.00 per share.

On March 5, 2021, IMARA Inc. reported its financial results for the year ended December 31, 2020, which included a net loss of $49.2 million, compared to a net loss of $23.5 million for the prior year.

Shares of IMARA Inc. (NASDAQ: IMRA) declined to as low as $8.49 per share on March 5, 2021.

Those who purchased shares of IMARA Inc. (NASDAQ: IMRA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of IMARA Inc. (NASDAQ: IMRA) here

News-ID: 2260764 • Views: 308

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of CytoDyn Inc. (OTC: CYDY)
An investor, who purchased shares of CytoDyn Inc. (OTC: CYDY), filed a lawsuit over alleged violations of Federal Securities Laws by CytoDyn Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of CytoDyn Inc. (OTC: CYDY) have certain options and for certain investors are short and strict deadlines running. Deadline: May 17, 2021. OTC: CYDY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Long-Term Investors in shares of SolarWinds Corporat …
An investigation on was announced concerning potential breaches of fiduciary duties by certain directors and officers of SolarWinds Corporation. Investors who are current long term investors in SolarWinds Corporation (NYSE: SWI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: SWI stocks follows a lawsuit filed against SolarWinds Corporation
Update in Lawsuit for Investors in shares of Merit Medical Systems, Inc. (NYSE: …
An investor in Merit Medical Systems, Inc. (NYSE: MMSI) shares filed a lawsuit in December 2019, against Merit Medical Systems, Inc. over alleged violations of Federal Securities Laws. Investors who purchased shares of Merit Medical Systems, Inc. (NYSE: MMSI) prior to February 2019 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. After the market
Deadline on May 3rd coming up in Lawsuit for Investors in Velodyne Lidar, Inc. ( …
A deadline is coming up on May 3, 2021 in the lawsuit filed for certain investors of Velodyne Lidar, Inc. (NASDAQ: VLDR) over alleged securities laws violations by Velodyne Lidar, Inc. Investors who purchased shares of Velodyne Lidar, Inc. (NASDAQ: VLDR) have certain options and there are strict and short deadlines running. Deadline: May 3, 2021. NASDAQ: VLDR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for IMARA

Global Sickle Cell Anemia Therapeutics Market to Witness a Pronounce Growth Duri …
Market Research Report Store offers a latest published report on Sickle Cell Anemia Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 91 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/439913/global-sickle-cell-anemia-therapeutics-market Sickle cell disease (SCD) is
Sickle Cell Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player …
Sickle Cell Disease Pipeline Drugs Assessment Overview: Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result, a sickle-like shaped cell is
FDA grants orphan drug designation to sickle cell treatment
Imara therapeutics, a leading biopharmaceutical announced that US Food and Drug Administration have granted orphan drug designation to its novel drug, IMR-657 to treat patients with Sickle cell disease. Presently, IMR-657 is stepping towards its first clinical phase to investigate its safety and pharmo-kinetics in patients with sickle cell. The study is currently being examined over patients between the ages of 18-55 years having sickle cell. IMR-687 is an orally-administered selective